Q3 2023 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Conclusions
Financial performance
Immunology
remibrutinib - BTK inhibitor
NCT05030311 REMIX-1 (CLOU064A2301)
Indication
Phase
Chronic inducible urticaria
Phase 3
Patients
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
348
1. Proportion of participants with complete response in Total Fric Score;
symptomatic dermographism [ Time Frame: Week 12]
2. Proportion of participants with complete response in critical temperature
threshold; cold urticaria [ Time Frame: Week 12]
3. Proportion of participants with itch numerical rating scale =0; cholinergic
urticaria [ Time Frame: Week 12]
All arms oral, twice daily:
Arm 1 Experimental Remibrutinib, symptomatic dermographism group
Arm 2 Placebo symptomatic dermographism group
Arm 3 Experimental Remibrutinib, cold urticaria group
Arm 4 Placebo cold urticaria group
Arm 5 Experimental Remibrutinib, cholinergic urticaria group
Arm 6 Placebo cholinergic urticaria group
Adults suffering from CINDU inadequately controlled by H1-antihistamines
Readout
Milestone(s)
2026
Publication
TBD
61 Investor Relations | Q3 2023 Results
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation